Dr. Annunziata on Olaparib and Cediranib Combination in Ovarian Cancer
Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.
Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.
In the phase II setting, an initial signal of activity and safety will be investigated for each of the 4 arms, explains Annunziata. Currently, there are no data regarding these drugs in the platinum-resistant setting.
This study will then move on to the phase III setting to compare the combination with the standard of care.
